Distribution of heparan sulfate oligosaccharides in murine mucopolysaccharidosis type IIIA

Metabolites

Volumn 4, Issue 4, 2014, Pages 1088-1100

  Mason, Kerryn ^a   Meikle, Peter ^b   Hopwood, John ^c   Fuller, Maria ^d  

^a FORENSIC SCIENCE SA   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Electrospray ionization tandem mass spectrometry; Heparan sulfate; Lysosomal storage disorder; Mouse model; Mucopolysaccharidosis type IIIA; Oligosaccharides; Reverse phase high performance liquid chromatography

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARAN SULFATE; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; TETRASACCHARIDE; URONIC ACID;

ANIMAL DISEASE; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BRAIN; CATABOLISM; CREATININE URINE LEVEL; DRUG DISTRIBUTION; ELECTROSPRAY MASS SPECTROMETRY; HEART; KIDNEY; LIMIT OF DETECTION; LUNG; MOUSE; NONHUMAN; PROTEIN DETERMINATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SANFILIPPO SYNDROME; URINALYSIS;

MURINAE;

EID: 85016456375     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo4041088     Document Type: Article

References (33)

1. Neufeld, E.F.; Muenzer, J. The Mucopolysaccharidoses. In The Metabolic and Molecular Bases of Inherited Disease, 8th ed.; Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill: New York, NY, USA, 2001; pp. 3421-3452.
2. Blumenkrantz, N.; Asboe-Hansen, G. New method for quantitative determination of uronic acids. Anal. Biochem. 1973, 54, 484-489.
3. Roberts, A.L.K.; Thomas, B.J.; Wilkinson, A.S.; Fletcher, J.M.; Byers, S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res. 2006, 60, 309-314.
4. Anson, D.S.; McIntyre, C.; Thomas, B.; Koldej, R.; Ranieri, E.; Roberts, A.; Clements, P.R.; Dunning, K.; Byers, S. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Genet. Vaccines Therap. 2007, doi:10.1186/1479-0556-5-1.
5. McIntyre, C.; Roberts, A.L.D.; Ranieri, E.; Clements, P.R.; Byers, S.; Anson, D.S. Lentirviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol. Genet. MeTab. 2008, 93, 411-418.
6. Ramsay, S.L.; Meikle, P.J.; Hopwood, J.J. Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry. Mol. Genet. MeTab. 2003, 78, 193-204.
7. Fuller, M.; Rozaklis, T.; Ramsay, S.L.; Hopwood, J.J.; Meikle, P.J. Disease-Specific Markers for the Mucopolysaccharidoses. Pediatr. Res. 2004, 56, 733-738.
8. Fuller, M.; Meikle, P.J.; Hopwood, J.J. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 2004, 14, 443-450.
9. Fuller, M.; Brooks, D.A.; Evangelista, M.; Hein, L.K.; Hopwood, J.J.; Meikle, P.J. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol. Genet. MeTab. 2005, 84, 18-24.
10. Fuller, M.; Chau, A.; Nowak, R.C.; Hopwood, J.J.; Meikle, P.J. A defect in exo-degradative pathways provides insight into endo-degradation of heparan and dermatan sulfates. Glycobiology 2006, 16, 318-325.
11. Neilsen, T.C.; Rozek, T.; Hopwood, J.J.; Fuller, M. Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: Application to Hunter syndrome. Anal. Biochem. 2010, 402, 113-120.
12. Oguma, T.; Tomatsu, S.; Montano, A.M.; Ozazaki, O. Analytical method for the determination of disaccharides derived from keratan, heparan and dermatan sulfates in human serum and plasma by high-performance liquid chromatograpy/turbo ionspray ionization tandem mass spectrometry. Anal. Biochem. 2007, 368, 79-86.
13. Tomatsu, S.; Montano, A.M.; Oguma, T.; Dung, V.C.; Oikawa, H.; Gutierrez, M.L.; Yamaguchi, S.; Suzuki, Y.; Fukushi, M.; Barrera, L.A.; et al. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidosis and mucolipidoses II and III by tandem mass spectrometry. Mol. Genet. MeTab. 2010, 99, 124-131.
14. King, B.; Savas, P.; Fuller, M.; Hopwood, J.J.; Hemsley, K. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. Mol. Genet. MeTab. 2006, 87, 107-112.
15. Savas, P.; Hemsley, K.M.; Hopwood, J.J. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol. Genet. MeTab. 2004, 82, 273-285.
16. Hemsley, K.M.; Hopwood, J.J. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav. Brain. Res. 2005, 158, 191-199.
17. Hemsley, K.M.; King, B.; Hopwood, J.J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. MeTab. 2006, 90, 313-328.
18. Hemsley, K.M.; Beard, H.; King, B.M.; Hopwood, J.J. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes. Brain. Behav. 2008, 7, 740-753.
19. Hemsley, K.M.; Luck, A.J.; Crawley, A.C.; Hassiotis, S.; Beard, H.; King, B.; Rozek, T.; Rozaklis, T.; Fuller, M.; Hopwood, J.J. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur. J. Neurosci. 2009, 29, 1197-1214.
20. Mason, K.E.; Meikle, P.J.; Hopwood, J.J.; Fuller, M. Characterization of sulfated oligosaccharides in mucopolysaccharidosis type IIIA by electrospray ionization mass spectrometry. Anal. Chem. 2006, 78, 4534-4542.
21. Nakajima, M.; Irimura, T.; di Ferrante, N.; Nicolson, G.L. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J. Biol. Chem. 1984, 259, 2283-2290.
22. Bame, K.J.; Robson, K. Heparanases produce distinct populations of heparan sulfate glycosaminoglycans in Chinese hamster ovary cells. J. Biol. Chem. 1997, 272, 2245-2251.
23. Hulett, M.D.; Freeman, C.; Hamdorf, B.J.; Baker, R.T.; Harris, M.J.; Parish, C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 1999, 5, 803-809.
24. Okada, Y.; Yamada, S.; Toyoshima, M.; Dong, J.; Nakajima, M.; Sugahara, K. Stuctural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. J. Biol. Chem. 2002, 277, 42488-42495.
25. Bame, K.J. Heparanases: Endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 2001, 11, 91R-98R.
26. Koliopanos, A.; Friess, H.; Kleeff, J.; Shi, X.; Liao, Q.; Pecker, I.; Vlodavsky, I.; Zimmermann, A.; Buchler, M.W. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001, 61, 4655-4659.
27. Varchalama, E.; Rodolakis, A.; Strati, A.; Papageorgiou, T.; Valavanis, C.; Vorgias, G.; Lianidou, E.; Antsaklis, A. Quantitative analysis of heparanse gene expression in normal cervical, cervical intraepithelial neoplastic, and cervical carcinoma tissues. Int. J. Gynecol. Cancer 2009, 19, 1614-1619.
28. Levidiotis, V.; Freeman, C.; Tikellis, C.; Cooper, M.E.; Power, D.A. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J. Am. Soc. Nephrol. 2004, 15, 68-78.
29. Parish, C.R.; Freeman, C.; Hulett, M.D. Heparanase: A key enzyme involved in cell invasion. Biophys. Acta. 2001, 1471, M99-M108.
30. Naparstek, Y.; Cohen, I.R.; Fuks, Z.; Vlodavsky, I. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984, 310, 241-244.
31. Arfi, A.; Richard, M.; Gandolphe, C.; Bonnefont-Rousselot, D.; Thérond, P.; Schermann, D. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol. Genet. MeTab. 2011, 103, 18-25.
32. Bhaumik, M.; Muller, V.J.; Rozaklis, T.; Johnson, L.; Dobrenis, K.; Bhattacharyya, R.; Wurzelmann, S.; Finamore, P.; Hopwood, J.J.; Walkley, S.U.; et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999, 9, 1389-1396.
33. Li, H.H.; Yu, W.H.; Rozengurt, N.; Zhao, H.Z.; Lyons, K.M.; Anagnostaras, S.; Fanselow, M.S.; Suzuki, K.; Vanier, M.T.; Neufeld, E.F. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. PNAS 1999, 96, 14505-14510.